Exelixis, Inc. $EXEL Shares Purchased by Voya Investment Management LLC

Voya Investment Management LLC lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 21.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 327,296 shares of the biotechnology company’s stock after acquiring an additional 56,708 shares during the quarter. Voya Investment Management LLC owned 0.12% of Exelixis worth $12,084,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC increased its stake in shares of Exelixis by 32.2% in the first quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 1,328 shares during the period. Belpointe Asset Management LLC acquired a new stake in shares of Exelixis in the first quarter worth $572,000. Park Avenue Securities LLC increased its stake in shares of Exelixis by 10.6% in the first quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company’s stock worth $272,000 after acquiring an additional 707 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Exelixis by 23.9% in the first quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company’s stock worth $9,159,000 after acquiring an additional 47,845 shares during the period. Finally, Fortis Capital Advisors LLC acquired a new stake in shares of Exelixis in the first quarter worth $572,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Bank of America increased their price target on shares of Exelixis from $45.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, June 5th. Stephens raised shares of Exelixis from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $29.00 to $60.00 in a report on Tuesday, June 24th. UBS Group set a $38.00 price target on shares of Exelixis and gave the stock a “neutral” rating in a report on Wednesday, July 30th. Guggenheim reissued a “buy” rating and set a $45.00 price target on shares of Exelixis in a report on Tuesday, July 29th. Finally, Stifel Nicolaus increased their price target on shares of Exelixis from $38.00 to $41.00 and gave the stock a “hold” rating in a report on Tuesday, July 29th. Thirteen investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $44.06.

Exelixis Stock Performance

NASDAQ:EXEL opened at $39.14 on Wednesday. The company has a fifty day moving average of $39.78 and a two-hundred day moving average of $39.65. The stock has a market capitalization of $10.54 billion, a PE ratio of 18.82, a P/E/G ratio of 0.80 and a beta of 0.32. Exelixis, Inc. has a fifty-two week low of $25.17 and a fifty-two week high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. Research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.